Get started
Author

Venkat Jasti

Observed name: V. Jasti
Observed institution: Suven Life Sciences (India)
OpenAlex ID: A5065706972
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
2023 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · Biomolecules · 52
PDF
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
2017 · Ramakrishna Nirogi, Anil Shinde, et al. · Journal of Medicinal Chemistry · 47
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
2018 · Ramakrishna Nirogi, Renny Abraham, et al. · Behavioural Pharmacology · 38
Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
2022 · Ramakrishna Nirogi, John Ieni, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 31
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
2020 · Ramakrishna Nirogi, Abdul Rasheed Mohammed, et al. · Journal of Medicinal Chemistry · 28
Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity
2019 · Ramakrishna Nirogi, Anil Shinde, et al. · Journal of Medicinal Chemistry · 21
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease
2021 · Ramakrishna Nirogi, Abdul Rasheed Mohammed, et al. · Journal of Medicinal Chemistry · 18
Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
2022 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · International Journal of Geriatric Psychiatry · 17
PDF
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
2021 · Ramakrishna Nirogi, Vijay Benade, et al. · Psychopharmacology · 16
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
2024 · Ramakrishna Nirogi, Anil Shinde, et al. · Sleep Medicine · 10
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
2021 · Ramakrishna Nirogi, Venkata R Grandhi, et al. · Journal of Psychopharmacology · 9
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization
2022 · Ramakrishna Nirogi, Renny Abraham, et al. · Psychopharmacology · 8
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
2022 · Ramakrishna Nirogi, Vinod Kumar Goyal, et al. · Neurology and Therapy · 7
PDF
P1‐252: Safety, tolerability and pharmacokinetics of SUVN‐502 ‐ A 5‐HT6 receptor antagonist, first in human phase‐1 Single Ascending Dose (SAD) study
2009 · Ramakrishna Nirogi, Vishwottam Kandikere, et al. · Alzheimer s & Dementia · 6
Masupirdine (SUVN‐502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimer’s disease
2020 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · Alzheimer s & Dementia · 5
Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease (5090)
2020 · Ramakrishna Nirogi, Anil Shinde, et al. · Neurology · 4
Masupirdine (SUVN-502): An Update on the Phase-3 Clinical Development Program Targeting Agitation in Patients with Dementia of Alzheimer’s Type (P1-3.020)
2025 · Ramakrishna Nirogi, Jyothsna Ravula, et al. · Neurology · 3
P1‐251: SUVN‐502: A safe, potent, selective, brain penetrant and orally active 5‐HT6 receptor antagonist ‐ first in human clinical phase‐1 study
2009 · Ramakrishna Nirogi, Ramasastri Kambhampati, et al. · Alzheimer s & Dementia · 3
Masupirdine in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Subgroup analyses of memantine regimen, plasma concentrations and duration of treatment
2020 · Ramakrishna Nirogi, Vinod Kumar Goyal, et al. · Alzheimer s & Dementia · 2
PDF
P1‐253: Human phase‐1 Multiple Ascending Dose (MAD) study ‐ safety, tolerability and pharmacokinetics of SUVN‐502, a 5‐HT6 receptor antagonist
2009 · Ramakrishna Nirogi, Vishwottam Kandikere, et al. · Alzheimer s & Dementia · 2
Samelisant (SUVN-G3031): Positive Results from Phase-2 Proof-of-concept, Double-blind, Placebo-controlled Study in Patients with Narcolepsy and an Update on Further Clinical Development (S6.004)
2025 · Ramakrishna Nirogi, Jyothsna Ravula, et al. · Neurology · 1
Samelisant (SUVN-G3031) - Topline Results from the Phase-2 Proof-of-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy (P10-9.002)
2024 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · Neurology · 1
Masupirdine (SUVN‐502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patient’s age on efficacy endpoints
2020 · Ramakrishna Nirogi, Anil K Shinde, et al. · Alzheimer s & Dementia · 1
PDF
Masupirdine (SUVN-502), a 5-HT6 receptor antagonist in combination with Donepezil and Memantine in moderate Alzheimer’s patients (5514)
2020 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · Neurology · 1
P2‐264: A safe, potent, selective brain penetrant and orally active 5‐HT6 receptor antagonist SUVN‐502
2009 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · Alzheimer s & Dementia · 1
Works count: 40
Citation count: 332
H-index: 10
I10-index: 10
Year
Topic
Type